Delay in Clozapine Initiation in Patients with Treatment-Resistance Schizophrenia Presenting Tertiary Psychiatric Facilities
DOI:
https://doi.org/10.51253/pafmj.v74i3.11530Keywords:
Clozapine initiation, Delay, Treatment-resistant schizophreniaAbstract
Objective: To determine the delay in Clozapine initiation in patients with treatment-resistance schizophrenia who presented to the Tertiary psychiatric facilities.
Study Design: Cross-sectional study.
Place and Duration of Study: Department of Psychiatry Combined Military Hospital, Peshawar and Department of Psychiatry Combined Military Hospital, Nowshera Pakistan, from Jan to Dec 2023.
Methodology: We recruited 103 treatment-resistant schizophrenia and Clozapine naïve patients after obtaining their consent. Patients were included by reviewing their medical history and records. The diagnosis was made by clinical interview and use of Positive and Negative syndrome scale. The data were recorded using a semi-structured questionnaire.
Results: Out of 103 patients, 78(75.7%) were male and 25(24.3%) were female. Regarding the initiation of Clozapine treatment, the mean duration from diagnosis to treatment initiation was 6.23±4.82 years. Patients were categorised based on the time to Clozapine initiation into early initiators (≤4 years), intermediate initiators (>4 years to <15 years), and delayed initiators (>15 years). The distribution across these categories was 51(49.5%) for early initiators, 47(45.6%) for intermediate initiators, and 5(4.9%) for delayed initiators.
Conclusion: There is a significant delay in Clozapine initiation despite adequate evidence to initiate it early. Clinicians should start Clozapine whenever there is a need.
Downloads
References
Nucifora FC, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis 2019; 131: 104257.
https://doi.org/10.1016/J.NBD.2018.08.016
Thien K, O’Donoghue B. Delays and barriers to the commencement of Clozapine in eligible people with a psychotic disorder: A literature review. Early Interv Psychiatry 2019; 13(1): 18-23. https://doi.org/ 10.1111/eip.12683
Hatano M, Kamei H, Takeuchi I, Gomi K, Sakakibara T, Hotta S, et al. Long-term outcomes of delayed Clozapine initiation in treatment-resistant schizophrenia: a multicenter retrospective cohort study. BMC Psychiatry 2023; 23(1): 673.
https://doi.org/ 10.1186/s12888-023-05176-y
Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014; 14: 102. https://doi.org/10.1186/1471-244X-14-102
Kane J. Clozapine for the Treatment-Resistant Schizophrenic. Arch Gen Psychiatry 1988; 45(9): 789-96.
https://doi.org/ 10.1001/archpsyc.1988.01800330013001
Taylor DM, Young C. Prior antipsychotic prescribing in patients currently receiving Clozapine: a case note review. J Clin Psy-chiatry 2003; 64(1): 30-34. https://doi.org/ 10.4088/jcp.v64n0107
Wheeler AJ, Feetam CL, Harrison J. Pathway to Clozapine Use: A Comparison Between a Patient Cohort from New Zealand and a Cohort from the United Kingdom. Clin Drug Investig 2014; 34(3): 203-211.
https://doi.org/10.1007/s40261-013-0166-x
Iruretagoyena B, Castañeda CP, Mena C, Diaz C, Nachar R, Ramirez-Mahaluf JP, et al. Predictors of Clozapine discontinuation at 2years in treatment-resistant schizophrenia. Schizophr Res 2021: 235: 102-108.
https://doi.org/10.1016/j.schres.2021.07.024
Trinczek E, Heinzel-Gutenbrunner M, Haberhausen M, Bachmann CJ. Time to Initiation of Clozapine Treatment in Children and Adolescents with Early-Onset Schizophrenia. Pharmacopsychiatry 2016; 49: 254–259.
https://doi.org/10.1055/s-0042-116947
Grover S, Hazari N, Chakrabarti S, Avasthi A. Delay in initiation of Clozapine: a retrospective study from a tertiary care hospital in North India. Psychiatry Res 2015; 226: 181–185.
https://doi.org/ 10.1016/j.psychres.2014.12.046
Muñoz-Manchado LI, Perez-Revuelta JI, Banerjee A, Galindo-Guarin L, Bernardo M, González-Saiz F, et al. Influence of time to Clozapine prescription on the clinical outcome. Schizophr Res 2023: S0920-9964(23)00339-0.
https://doi.org/:10.1016/j.schres.2023.09.028
Yoshimura B, Yada Y, So R, Takaki M, Yamada N. The critical treatment window of Clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study. Psychiatry Res 2017; 250: 65–70.
https://doi.org/10.1016/j.psychres.2017.01.064
Shah P, Iwata Y, Plitman E, Brown EE, Caravaggio F, Kim J, et al. The impact of delay in Clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. Psychiatry Res 2018; 268: 114–122.
https://doi.org/10.1016/j.psychres.2018.06.070
Jones R, Upthegrove R, Price MJ, Pritchard M, Chandan JS, Legge S, et al. Duration of prior psychotic illness and Clozapine response: a retrospective observational study using electronic health records. Ther Adv Psychopharmacol 2022; 12.
https://doi.org/10.1177/20451253221103353
Chan SKW, Chan HYV, Honer WG, Bastiampillai T, Suen YN, Yeung WS, et al. Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders. Schizophr Bull 2021; 47: 485–494.
https://doi.org/ 10.1093/schbul/sbaa145
Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, et al. International trends in Clozapine use: a study in 17 countries. Acta Psychiatr Scand 2017; 136: 37–51.
https://doi.org/10.1111/acps.12742
Xu SW, Dong M, Zhang Q, Yang SY, Chen LY, Sim K, et al. Clozapine prescription pattern in patients with schizophrenia in Asia: The REAP survey (2016). Psychiatry Res 2020; 287.
https://doi.org/10.1016/j.psychres.2019.02.056
Jones R, MacCabe JH, Price MJ, Liu X, Upthegrove R. Effect of age on the relative efficacy of Clozapine in schizophrenia. Acta Psychiatr Scand 2020; 142: 109–120.
https://doi.org/ 10.1111/acps.13156
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Asad Ullah Jan, Sajid Rahim
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.